MARKET

GERN

GERN

Geron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.680
+0.020
+1.20%
After Hours: 1.670 -0.01 -0.60% 17:48 08/07 EDT
OPEN
1.600
PREV CLOSE
1.660
HIGH
1.695
LOW
1.560
VOLUME
2.98M
TURNOVER
--
52 WEEK HIGH
2.400
52 WEEK LOW
0.7500
MARKET CAP
521.42M
P/E (TTM)
-4.3670
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GERN stock price target is 3.500 with a high estimate of 4.000 and a low estimate of 3.000.

EPS

GERN News

More
Geron Corp (GERN) CEO John Scarlett on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 1d ago
Geron EPS in-line, misses on revenue
Geron (NASDAQ:GERN): Q2 GAAP EPS of -$0.06 in-line. Revenue of $0.04M (-60.0% Y/Y) misses by $0.02M. Press Release
seekingalpha · 1d ago
Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events
Business Wire · 2d ago
Geron to Present at the BTIG Virtual Biotechnology Conference
Business Wire · 4d ago
MPC, GERN among premarket gainers
Seeking Alpha - Article · 5d ago
Geron shares are trading higher after an analyst at Stifel initiated coverage on the company's stock with a Buy rating.
Benzinga · 5d ago
Geron started at buy with $3 stock price target at Stifel Nicolaus
marketwatch.com · 5d ago
Penny Stocks to Buy Using Technical Analysis for August 2020
The economy has been tumultuous, but technical analysis helps us see through the static and zero in on the best penny stock opportunities.
Investopedia · 07/31 17:39

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About GERN

Geron Corporation (Geron) is a late-stage clinical biopharmaceutical company, which is focused on development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat includes IMerge, a Phase II/III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis.
More

Webull offers kinds of Geron Corporation stock information, including NASDAQ:GERN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GERN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GERN stock methods without spending real money on the virtual paper trading platform.